Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00863304 |
Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis
Condition | Intervention | Phase |
---|---|---|
Osteoarthritis |
Biological: tanezumab 10 mg Biological: tanezumab 5 mg Drug: naproxen Other: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study of the Analgesic Efficacy And Study of Tanezumab in Patients With Osteoarthritis Of The Hip |
Estimated Enrollment: | 800 |
Study Start Date: | May 2009 |
Estimated Study Completion Date: | July 2010 |
Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Biological: tanezumab 10 mg
tanezumab 10 mg one dose at weeks 0 and 8
|
2: Experimental |
Biological: tanezumab 5 mg
tanezumab 5 mg one dose at weeks 0 and 8
|
3: Active Comparator |
Drug: naproxen
naproxen 1000 mg daily for 16 weeks
|
4: Placebo Comparator |
Other: placebo
placebo to match tanezumab and naproxen dosing
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A4091018 |
Study First Received: | March 13, 2009 |
Last Updated: | April 2, 2009 |
ClinicalTrials.gov Identifier: | NCT00863304 History of Changes |
Health Authority: | United States: Food and Drug Administration |
monoclonal antibody
RN624
PF-04383119
nerve growth factor
anti-nerve growth factor
OA
pain
arthritis |
Anti-Inflammatory Agents Naproxen Osteoarthritis Joint Diseases Cyclooxygenase Inhibitors Pain Osteoarthritis, Hip Rheumatic Diseases Antibodies, Monoclonal Antibodies |
Musculoskeletal Diseases Analgesics, Non-Narcotic Arthritis Mitogens Anti-Inflammatory Agents, Non-Steroidal Peripheral Nervous System Agents Analgesics Antirheumatic Agents Immunoglobulins |
Anti-Inflammatory Agents Naproxen Molecular Mechanisms of Pharmacological Action Osteoarthritis Joint Diseases Cyclooxygenase Inhibitors Physiological Effects of Drugs Enzyme Inhibitors Osteoarthritis, Hip Rheumatic Diseases Gout Suppressants |
Pharmacologic Actions Musculoskeletal Diseases Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Arthritis Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |